The global eczema therapeutics market is estimated to be valued at US$ 15,453.4 million in 2021 and is expected to exhibit a CAGR of 11.1% over the forecast period, as highlighted in a new report published by Coherent Market Insights.
Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/4630
Market Overview:
Eczema, or atopic dermatitis, is a skin condition that causes patches of itchiness, inflammation, swelling, and cracked skin. It’s common in children but can occur at any age. Symptom may include itchy, dry, rough, flakey, inflamed, and irritated skin. It can flare up, subside, and then flare up again. There are several types of eczema, but the most common is atopic dermatitis. There is currently no cure for eczema. Treatment aims to heal the affected skin and prevent flares of symptoms, and is based on an individual’s age, symptoms, and current state of health. OTC hydrocortisone is often the first thing doctors recommend to treat mild eczema. In some serious cases, antibiotics are also prescribed if skin infection is detected. Diagnosis of eczema is mostly based on physical examination and in few cases, skin biopsy is performed. Eczema therapeutics help reduce inflammation and relieve skin itchiness.
Competitive Landscape:
Major players operating in the global eczema therapeutics market are Pfizer Inc, AstraZeneca plc, GlaxoSmithKline plc, Meda AB, Anacor Pharmaceuticals Inc., Astellas Pharma Inc., F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals Inc., Novartis AG, Sanofi, AbbieVie Inc., and Encore Dermatology Inc, among others.
Key Market Drivers:
Increasing demand for eczema therapeutics due to the increasing prevalence of eczema across the globe is expected to propel growth of the eczema therapeutics market during the forecast period. For instance, in February 2021, Incyte Corporation announced that the U.S. Food and Drug Administration (USFDA) has accepted the New Drug Application (NDA) for ruxolitinib cream for the treatment of atopic dermatitis, a type of eczema.
Moreover, rising campaigns to raise eczema awareness, government funds to support research and development activities, and increasing adoption of novel medications are some major factors expected to augment growth of the eczema therapeutics market. For instance, October is Eczema Awareness Month, and Itching for a Cure (IFAC) is National Eczema Association’s annual campaign to raise funds for eczema research.
COVID-19 Impact Analysis:
Management of chronic skin diseases during the pandemic has become a worldwide problem. Although people with eczema are not considered as high risk for contracting or developing severe symptoms of COVID-19, it is still essential to keep eczema symptoms under control to prevent flare-ups. Moreover, according to the National Eczema Society, there is no evidence to suggest that people with eczema are more likely to develop COVID-19 or to experience a severe form of the condition if they do develop it. This in turn is expected to have a positive impact on the growth of the market.
Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/4630
Key Takeaways:
- The eczema therapeutics market is expected to exhibit a CAGR of 11.1 % during the forecast period due to the frequent approvals and launches of novel devices worldwide. For instance, in May 2020, FDA approved Sanofi’s Dupixent (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis.
- Among regions, North America is expected to witness substantial growth in the eczema therapeutics market owing to the high prevalence of eczema, increasing awareness among people, increasing adoption of novel therapeutics, and increasing research and development activities in the region. For instance, according to the National Eczema Association, over 31.6 million Americans (10.1% of US population) have some form of eczema. Moreover, atopic dermatitis (AD) is the most common form of eczema and is chronic (long-lasting). According to the American College of Allergy, Asthma and Immunology, atopic dermatitis is estimated to account for about 10-20% for those having eczema.
Reasons to Purchase this Report
• Current and future of global Eczema Therapeutics Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/4630
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Regulatory Scenario
- PEST Analysis
- Recent Product Launch/Approval
- Epidemiology
- Mergers and Acquisitions
- Market Dynamics
- Global Eczema Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic
- Impact on Supply Chain
- Impact on Research and Development
- Government Initiatives
- Global Eczema Therapeutics Market, By Treatment, 2017-2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Emollients/Moisturizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Antihistamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Calcineurin inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Immunomodulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Interleukin inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Eczema Therapeutics Market, By Distribution Channel, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Eczema Therapeutics Market, By Region, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2018 – 2028
- Regional Trends
- North America
- Market Size and Forecast, By Treatment, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Treatment, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Treatment, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Treatment, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Treatment, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Treatment, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028 (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/eczema-therapeutics-market-3882
Click Here For Other Reports:
Interstitial Cystitis Drugs Market
Acute Kidney Injury Treatment Market
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837